Celebrating 25 Years of Scoop
Scoop InfoPages
This InfoPage in unregistered, if this is your news page register PHARMAC for InfoPages here.
PHARMAC - Latest News [Page 3]
Access To COVID-19 Antiviral Treatments Widened For More People At Risk
Wednesday, 20 September 2023, 11:02 am | PHARMAC
Te Pātaka Whaioranga – Pharmac is widening access to COVID-19 antivirals to people who are vulnerable to severe infection from COVID-19, including those with disabilities and with one or more severe health conditions. “We know antivirals can reduce the ... More >>
Pharmac Widens Access To Treatment For Life-long Bleeding Disorder, Severe Haemophilia A
Monday, 4 September 2023, 11:26 am | PHARMAC
Te Pātaka Whaioranga – Pharmac has confirmed it is widening access to emicizumab (branded as Hemlibra) for the treatment of people with severe haemophilia A without factor VIII inhibitors. “Widening access to this treatment will help people manage ... More >>
Pharmac Funds First Treatment For Primary Progressive Multiple Sclerosis
Monday, 4 September 2023, 11:12 am | PHARMAC
Te Pātaka Whaioranga – Pharmac has confirmed it is widening access to ocrelizumab (branded as Ocrevus) as the first funded treatment for primary progressive multiple sclerosis. “We’re pleased to have a treatment option for people living with primary ... More >>
Pharmac Taking Action To Ensure Supply Of Type 2 Diabetes Medicine Amid Worldwide Shortage
Tuesday, 29 August 2023, 2:45 pm | PHARMAC
Te Pātaka Whaioranga - Pharmac is taking steps to ensure people with type 2 diabetes who take dulaglutide (branded as Trulicity) can continue to access the treatment while we experience further supply chain issues on top of a global shortage. Dulaglutide ... More >>
Pharmac Seeking Bids From Suppliers For Multiple Myeloma Treatments
Thursday, 24 August 2023, 2:00 pm | PHARMAC
Te Pātaka Whaioranga - Pharmac is seeking bids from suppliers for two medicines, lenalidomide and pomalidomide, for use in the treatment of multiple myeloma. “We understand there is a high unmet health need for people with multiple myeloma,” ... More >>
Pharmac Confirms Transition To A Trastuzumab Biosimilar And Widens Access To Other Types Of Cancer
Wednesday, 23 August 2023, 1:48 pm | PHARMAC
Te Pātaka Whaioranga – Pharmac is transitioning to a trastuzumab biosimilar, Herzuma, from the currently funded brand, Herceptin, as a result of a competitive procurement process. The treatment is currently funded for people with metastatic ... More >>
Pharmac Calls For Applications From The Suppliers Of Vaccines That Protect Against COVID-19
Wednesday, 16 August 2023, 12:59 pm | PHARMAC
Te Pātaka Whaioranga – Pharmac is interested to hear from pharmaceutical suppliers who manufacture vaccines that protect against COVID-19 and offer the opportunity to submit funding applications for future consideration. “Pharmac is now responsible ... More >>
Pharmac Indicates Interest To Fund More Oestradiol Treatments To Relieve Supply Issue
Tuesday, 15 August 2023, 6:30 am | PHARMAC
Te Pātaka Whaioranga - Pharmac is planning to issue a competitive process for supply of oestradiol transdermal products in New Zealand. “Today we have issued a Future Procurement Opportunity for oestradiol transdermal products,” says Pharmac’s ... More >>
Pharmac Proposes Widening Access To A Brain Cancer Treatment To Help Reduce The Impact Of A Discontinuation
Friday, 11 August 2023, 9:06 am | PHARMAC
Te Pātaka Whaioranga – Pharmac is proposing to widen access to temozolomide, an oral anti-cancer treatment, for people with a type of brain cancer called glioma. This comes as lomustine, the current treatment option for people with low grade or ... More >>
Pharmac’s Rare Disorders Advisory Committee Makes New Recommendations For Funding
Thursday, 10 August 2023, 12:58 pm | PHARMAC
Te Pātaka Whaioranga – Pharmac has published the record of the March Rare Disorders Advisory Committee meeting, sharing details on a number of funding applications including those for spinal muscular atrophy (SMA). The Rare Disorders Advisory Committee meeting ... More >>
Pharmac Secures Supply Of Vaccines For New Zealanders
Thursday, 3 August 2023, 12:59 pm | PHARMAC
Te Pātaka Whaioranga – Pharmac has confirmed supply agreements for a range of funded vaccines including those that protect against influenza and meningococcal disease. This follows a request for proposals (RFP) competitive process. “We are ... More >>
Pharmac Considers Access Criteria For COVID-19 Antiviral Treatments
Tuesday, 1 August 2023, 2:58 pm | PHARMAC
Te Pātaka Whaioranga – Pharmac is consulting on changes to the access criteria for all COVID-19 antiviral treatments to include more people who are at risk of becoming severely ill from the infection. “We now know that these antiviral treatments can ... More >>
Pharmac Joins International Collaboration To Advance Use Of Health Technology Assessments
Thursday, 20 July 2023, 1:05 pm | PHARMAC
Pharmac has joined an international collaboration of government health technology assessment (HTA) agencies. Together with partners from Australia, the United Kingdom and Canada we're working to make health systems better by sharing HTA knowledge and ... More >>
Pharmac Seeking Bids From Suppliers For Continuous Glucose Monitors, Insulin Pumps And Consumables
Tuesday, 11 July 2023, 11:10 am | PHARMAC
Te Pātaka Whaioranga - Pharmac is seeking commercial bids from suppliers for the supply of funded continuous glucose monitors (CGMs), insulin pumps, and insulin pump consumables for people living with type 1 diabetes. “We are really pleased to be ... More >>
Pharmac Considers Widening Access To Treatments For Multiple Sclerosis And Haemophilia A
Thursday, 22 June 2023, 3:35 pm | PHARMAC
Te Pātaka Whaioranga - Pharmac has started a consultation today for widening access for two treatments; ocrelizumab (branded as Ocrevus) as the first funded treatment for primary progressive multiple sclerosis, and emicizumab (branded as Hemlibra) ... More >>
Pharmac Seeks Feedback On Widening Access And Transitioning To A Biosimilar Trastuzumab
Thursday, 8 June 2023, 2:10 pm | PHARMAC
Te Pātaka Whaioranga – Pharmac is considering awarding Principal Supply to a biosimilar brand of trastuzumab (branded as Herzuma), and widening access to include those with stomach (gastric) cancer, from 1 December 2023. Consultation on the proposal ... More >>
Pharmac Funds Second Treatment For Spinal Muscular Atrophy
Tuesday, 11 April 2023, 1:46 pm | PHARMAC
Te Pātaka Whaioranga - Pharmac has announced the funding of risdiplam (branded as Evrysdi) for people with the rare genetic disorder spinal muscular atrophy, who meet eligibility criteria from 1 May 2023. “We’re pleased to announce that we ... More >>
Pharmac Shares Next Steps In Reviewing Rule 8.1b
Wednesday, 5 April 2023, 11:06 am | PHARMAC
Te Pātaka Whaioranga – Pharmac’s consultation on rule 8.1b of the Pharmaceutical Schedule has now closed. “Rule 8.1b is a unique exception that means any medicine used to treat cancer in a paediatric setting is automatically funded without a Pharmac ... More >>
Pharmac Seeking Feedback On The COVID-19 Antiviral Molnupiravir
Tuesday, 4 April 2023, 11:58 am | PHARMAC
Te Pātaka Whaioranga – Pharmac are consulting on the role of molnupiravir in New Zealand’s portfolio of COVID-19 treatments. The consultation seeks feedback on whether Pharmac should stop funding the treatment or adjust the eligibility criteria ... More >>
Pharmac Considers Funding Rituximab For IgG4-related Disease
Thursday, 23 March 2023, 10:05 am | PHARMAC
Te Pātaka Whaioranga - Pharmac has initiated a consultation today on widening funded access to rituximab (branded as Riximyo) for people with IgG4-related disease, a chronic inflammatory condition. “Pharmac currently funds rituximab for several ... More >>
